U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients

Samuel B Ho, Bashar Aqel, Eric Dieperink, Shanglei Liu, Lori Tetrick, Yngve Falck-Ytter, Charles DeComarmond, Coleman I Smith, Daniel P McKee, William Boyd, Clark C Kulig, Edmund J Bini, Marcos C Pedrosa, Samuel B Ho, Bashar Aqel, Eric Dieperink, Shanglei Liu, Lori Tetrick, Yngve Falck-Ytter, Charles DeComarmond, Coleman I Smith, Daniel P McKee, William Boyd, Clark C Kulig, Edmund J Bini, Marcos C Pedrosa

Abstract

Background: Patients with chronic hepatitis C genotype 1 (HCV-1) and difficult-to-treat characteristics respond poorly to pegylated interferon alfa and ribavirin (RBV), and could benefit from an interferon with increased activity (consensus interferon or CIFN), favorable viral kinetics from daily dosing, and a longer duration of therapy. The purpose of this pilot study was to determine the efficacy and safety of daily CIFN + RBV for initial treatment of patients with HCV-1 infection.

Methods: Patients with difficult-to-treat characteristics (92% male, 33% African American, 78% Veterans Affairs [VA]; 67% high viral load, 59% stage 3-4 fibrosis, and mean weight of 204 lbs) were enrolled at seven VA and two community medical centers. They were randomized to daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B, n = 31).

Results: Intention to treat analysis for treatment groups A and B demonstrated 33% (11/33) and 32% (10/31) sustained virologic response (SVR), respectively. Only 2/31 patients in group B received more than 52 weeks of treatment. The overall group demonstrated a 31% (20/64) rapid virologic response rate (RVR), 54% (34/64) end of treatment virologic response and a 33% (21/64) SVR. Patients with RVR at 4 weeks, early virologic response from 8-12 weeks, and late virologic response from 16-24 weeks demonstrated SVR of 75% (15/20), 31% (4/13), and 22% (2/9), respectively. Overall early non-protocol discontinuation occurred in 26/64 (40%) patients.

Conclusion: Daily CIFN and ribavirin for initial treatment of HCV-1 patients has potential for achieving a relatively high RVR rate, but discontinuations are frequent and successful use of this regimen is highly dependent on adequate patient support to maintain adherence.

Figures

Fig. 1
Fig. 1
Study design and patient outcome
Fig. 2
Fig. 2
Patient outcomes. a Percentage of patients with negative hepatitis C virus polymerase chain reaction (HCV PCR) results over time for total cohort and patients in groups A and B. Results include HCV quantitative PCR negative (week 4–20) and HCV qualitative PCR negative (week 24, end of treatment [week 52+]) and end of follow up (week 72+) data. Note: patients who were HCV PCR negative but subsequently dropped out were considered as treatment failures from the time of drop out. b Sustained virologic response (SVR) analysis by study arm and overall SVR result for total cohort. Intention to treat (ITT) and overall per protocol SVR rates
Fig. 3
Fig. 3
Patient outcomes by study site. Sites with greater than eight patients enrolled were compared (sites A–D), and other study sites with lower enrollment were grouped together (other low enrollment sites). AA African American
Fig. 4
Fig. 4
Dose reductions. a Number and reasons for incidences of consensus interferon (CIFN) dose reduction. b Number and reasons for incidences of ribavirin (RBV) dose reduction
Fig. 5
Fig. 5
Number and reasons for incidences of treatment discontinuation

References

    1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714.
    1. Wong JB, McQuillan GM, McHutchison JG, et al. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000;90:1562–1569. doi: 10.2105/AJPH.90.10.1562.
    1. NIH National Institutes of Health consensus development conference statement: management of hepatitis C: 2002. Hepatology. 2002;36:S3–S15.
    1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. doi: 10.1016/S0140-6736(01)06102-5.
    1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. doi: 10.1056/NEJMoa020047.
    1. Jacobson IM, Brown RS, Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007;46:971–981. doi: 10.1002/hep.21932.
    1. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon Alfa-2b or Alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593. doi: 10.1056/NEJMoa0808010.
    1. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. Veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100:1772–1779. doi: 10.1111/j.1572-0241.2005.41860.x.
    1. Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46:37–47. doi: 10.1002/hep.21662.
    1. Blatt LM, Davis JM, Klein SB, et al. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996;16:489–499. doi: 10.1089/jir.1996.16.489.
    1. Ozes ON, Reiter Z, Klein S, et al. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res. 1992;12:55–59.
    1. Klein SB, Blatt LM, Taylor MW. Consensus interferon induces peak mRNA accumulation at lower concentrations than interferon-alpha 2a. J Interferon Res. 1993;13:341–347.
    1. Klein SB, Blatt LM, Taylor MW. Cell surface binding characteristics correlate with consensus type I interferon enhanced activity. J Interferon Cytokine Res. 1996;16:1–6. doi: 10.1089/jir.1996.16.1.
    1. Kaiser S, Hass H, Gregor M. High dose induction therapy with consensus interferon and ribavirin for treatment—naive patients with hepatitis C. Hepatology. 2002;36:362A. doi: 10.1016/S0168-8278(01)00285-9.
    1. Kaiser S, Hass H, Gregor M. Successful retreatment of peginterferon nonresponder patients with chronic hepatitis C with high dose consensus interferon induction therapy. Gastroenterology. 2004;126:A668.
    1. Sjogren MH, Sjogren R, Jr, Lyons MF, et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig Dis Sci. 2007;52:1540–1547. doi: 10.1007/s10620-007-9757-9.
    1. Leevy CB. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig Dis Sci. 2008;53:1961–1966. doi: 10.1007/s10620-007-0076-y.
    1. Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009;49:1838–1846. doi: 10.1002/hep.22871.
    1. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086–1097. doi: 10.1053/j.gastro.2006.02.015.
    1. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451–460. doi: 10.1053/j.gastro.2006.05.016.
    1. Pockros PJ, Reindollar R, McHutchinson J, et al. The safety and tolerability of daily infergen plus ribavirin in the treatment of naive chronic hepatitis C patients. J Viral Hepat. 2003;10:55–60. doi: 10.1046/j.1365-2893.2003.00402.x.
    1. Kaiser S, Lutze B, Sauter B, et al. Retreatment of HCV genotype 1 relapse patients to peginterferon/ribavirin therapy with an extended treatment regimen of 72 weeks with consensus interferon/ribavirin versus peginterferon alpha/ribavirin. Hepatology. 2007;46:819A.
    1. Pearlman B, Ehleben C. Retreatment of chronic hepatitis C genotype 1 infected relapsers to peginterferon/ribavirin with consensus interferon/ribavirin or with extended duration therapy peginterferon/ribavirin. Hepatology. 2009;50:686A.
    1. Chainuvati S, Khalid SK, Kancir S, et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. J Viral Hepat. 2006;13:235–241. doi: 10.1111/j.1365-2893.2005.00681.x.
    1. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101:2254–2262. doi: 10.1111/j.1572-0241.2006.00731.x.
    1. Groom H, Dieperink E, Nelson DB, et al. Outcomes of a hepatitis C screening program at a large urban VA Medical Center. J Clin Gastroenterol. 2008;42:97–106. doi: 10.1097/MCG.0b013e31802dc56f.
    1. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705–716. doi: 10.1016/S0140-6736(10)60934-8.
    1. Brau N, Bini EJ, Currie S, et al. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat. 2006;13:242–249. doi: 10.1111/j.1365-2893.2005.00682.x.
    1. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅